Pediatric Blood & Cancer · 2014 · 60 citations · 21 references
MedicineOncologyPediatricsChemotherapyNeuro-oncologyPediatric OncologyBrain TumorsChemotherapy Toxicity ManagementCraniospinal IrradiationHigh-dose ChemotherapyPediatric Brain TumorsPediatric Neuro-oncologyAutologous Stem Cell InfusionAutologous Stem Cell TherapyConventional External Beam RadiotherapyMedulloblastoma ChemotherapyMedulloblastoma IrradiationMedulloblastoma RadiotherapyPediatric Brain Tumor RadiotherapyPediatric Craniospinal Irradiation
BACKGROUND: To assess the feasibility and effectiveness of high-dose chemotherapy (HDC) with stem cell support followed by conventional craniospinal radiotherapy (RT) as treatment for children older than 5 years of age with newly diagnosed high-risk medulloblastoma (MB) or supratentorial PNET (sPNET). PROCEDURE: Between May 2001 and April 2010, 24 children older than 5 years of age (MB = 21; sPNET = 3), fulfilling inclusion criteria at diagnosis, were treated at Gustave Roussy. After conventional chemotherapy, they received two courses of high-dose thiotepa (600 mg/m(2)) followed by craniospinal RT. RESULTS: The median follow-up was 4.4 years (range, 0.8-11.3 years). For children with metastatic MB, the 5-year event-free survival (EFS) and overall survival (OS) were 72% and 83%, respectively. The toxicity was manageable. No toxic death occurred. At the most recent evaluation, among the 24 children who had at least one Full Scale Intellectual Quotient (FSIQ) examination at a median follow-up of 3.79 years after diagnosis, the mean estimated FSIQ was 82 (range, 56-114). CONCLUSIONS: In children with metastatic MB, tandem HDCT with ASCT followed by conventional craniospinal RT proved its feasibility without jeopardizing survival.
21
Amar Gajjar, Murali Chintagumpala, David M. Ashley et al. · The Lancet Oncology · 2006 · 949 citations · Full text
Medicine, Oncology, Pediatrics +17
Paul M. Zeltzer, James M. Boyett, Jonathan L. Finlay et al. · Journal of Clinical Oncology · 1999 · 756 citations
Medicine, Oncology, Pediatrics +17